Abstracts tagged "Anti-TNF Drugs"

Abstract Number: 0287 • ACR Convergence 2022
Association Between Short-Term Response to Upadacitinib Treatment and Long-Term Clinical Outcomes in Patients with Rheumatoid Arthritis and Prior Inadequate Response to Tumor Necrosis Factor Inhibitor Therapy
Christina Charles-Schoeman¹, Roy Fleischmann², Stephen Hall³, Arthur Kavanaugh⁴, Andrea Rubbert-Roth⁵, Ryan DeMasi⁶, Sara Penn⁶, Andrew Garrison⁶, Samuel Anyanwu⁶, Radames Sierra-Zorita⁷ and Ricardo Xavier⁸, ¹Division of Rheumatology, University of California, Los Angeles, Santa Monica, CA, ²University of Texas Southwestern Medical Center and Metroplex Clinical Research Center, Dallas, TX, ³Emeritus Research and Monash University, Melbourne, Australia, ⁴University of California San Diego, La Jolla, CA, ⁵Division of Rheumatology, Cantonal Clinic St Gallen, St.Gallen, Switzerland, ⁶AbbVie, Inc., North Chicago, IL, ⁷University of Puerto Rico, San Juan, Puerto Rico, ⁸Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil
Background/Purpose: Early predictors of response to treatment with upadacitinib (UPA), an oral Janus kinase inhibitor, could help to optimize a treat-to-target approach in patients with…
Abstract Number: 0798 • ACR Convergence 2022
Uncovering the Relationship Between COVID-19 Outcome Severity and Rheumatic Disease
Natalie Allcott¹, Neha Gupta¹, Namita Raghavan¹, Huzaefah Syed² and Stamatina Danielides³, ¹VCU, Richmond, VA, ²Virginia Commonwealth University Medical Center, Richmond, VA, ³Virginia Commonwealth University Health System, Glen Allen, VA
Background/Purpose: The COVID-19 pandemic has caused great concern amongst immunocompromised patients, especially those with rheumatic diagnoses. While much has been learned in the past two…
Abstract Number: 1567 • ACR Convergence 2022
Refractory Macular Edema Due to Behçet’s Disease. Multicenter Comparative Study of Adalimumab and Certolizumab Pegol
José Luis Martín-Varillas¹, Lara Sánchez-Bilbao², Vanesa Calvo Río³, Alf Adán⁴, Inés Hernanz Rodríguez⁴, Miguel Cordero Coma⁵, David Díaz Valle⁶, Patricia Fanlo⁷, Juan Ramón de Dios⁸, A. Garcia-Aparicio⁹, Sergio Rodriguez Montero¹⁰, Vega Jovani Casano¹¹, Patricia Moya Alvarado¹², eva Peña Sainz-Pardo¹³, José Luis Hernández² and Ricardo Blanco¹⁴, ¹Hospital de Laredo, Laredo, Cantabria, Spain, ²Hospital Universitario Marqués de Valdecilla, Santander, Spain, ³Valdecilla Hospital, Santander, Spain, ⁴H. Clinic, Barcelona, Spain, ⁵Hospital de León, León, Spain, ⁶Hospital Clínico San Carlos, Madrid, Spain, ⁷Complejo Hospitalario de Navarra, Navarra, Spain, ⁸Hospital de Araba, Araba, Spain, ⁹Hospital Universitario de Toledo, Toledo, Spain, ¹⁰Virgen de Valme University Hospital, Sevilla, Spain, ¹¹National Health system, Alicante, Spain, ¹²Hospital Parc Tauli, Barcelona, Spain, ¹³Hospital Universitario 12 de Octubre, Madrid, Spain, ¹⁴Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain
Background/Purpose: Cystoid Macular Edema (CME) is the leading cause of blindness in non-infectious uveitis. Behçet's disease (BD) is one of the diseases most frequently associated…
Abstract Number: 2218 • ACR Convergence 2022
Frailty Is Associated with Serious Infections in Biologic and Targeted-synthetic DMARD Treated Patients with Rheumatoid Arthritis
Namrata Singh¹, Laura Gold², Katherine Wysham³, James Andrews², Pankti Reid⁴, Una Makris⁵, Bryant England⁶, Jiha Lee⁷, Michael George⁸, Joshua Baker⁹, Jeffrey Jarvik², Patrick Heagerty² and Siddharth Singh¹⁰, ¹University of Washington, Bellevue, WA, ²University of Washington, Seattle, WA, ³VA Puget Sound/University of Washington, Seattle, WA, ⁴University of Chicago Medical Center, Chicago, IL, ⁵UT Southwestern Medical Center and Dallas VA, Dallas, TX, ⁶University of Nebraska Medical Center, Omaha, NE, ⁷University of Michigan, Ann Arbor, MI, ⁸University of Pennsylvania, Philadelphia, PA, ⁹University of Pennsylvania and Corporal Michael J. Crescenz VA Medical Center, Philadelphia, ¹⁰University of California San Diego, San Diego
Background/Purpose: Recently, it has been recognized that frailty and pre-frailty are common in patients with rheumatoid arthritis (RA) [1]. Whether frailty status portends an increased…
Abstract Number: 0289 • ACR Convergence 2022
Real-world Data of Tofacitinib versus Tumor Necrosis Factor Inhibitors in Taiwanese Patients with Rheumatoid Arthritis from a Drug-based Registry
Song-Chou Hsieh¹, Wei-Sheng Chen², Jui-Chieh Hu³, Wan-Yu Sung⁴, Wen-Chan Tsai⁴, Hsiang-Cheng Chen⁵, Chung-Ming Huang⁶, Edward Kuo⁷, James Wee⁸, John Woolcott⁹ and Yi-Hsing Chen¹⁰, ¹Division of Rheumatology, Immunology and Allergy, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan, ²Division of Allergy, Immunology & Rheumatology, Department of Medicine, Taipei Veterans General Hospital; Faculty of Medicine, National Yang-Ming University, Taipei, Taiwan, ³Division of Allergy, Immunology and Rheumatology, Department of Medicine, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan, ⁴Department of Allergy, Immunology, and Rheumatology, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan, ⁵Division of Immunology, Rheumatology, and Allergy, Department of Medicine, Tri-Service General Hospital, Taipei, Taiwan, ⁶Division of Immunology and Rheumatology, Department of Internal Medicine, China Medical University Hospital, Taichung, Taiwan, ⁷Pfizer Ltd, Taipei, Taiwan, ⁸Pfizer Inc, Makati City, Philippines, ⁹Pfizer, Inc, Collegeville, PA, ¹⁰Division of Allergy, Immunology and Rheumatology, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA and was approved under Taiwan's National Health Insurance (NHI) reimbursement system in…
Abstract Number: 0809 • ACR Convergence 2022
Ex Vivo Comparative Immunogenicity Assessment (EVCIA) to Determine Relative Immunogenicity in Chronic Plaque Psoriasis in Participants Receiving Humira® or Undergoing Repeated Switches Between Humira and AVT02
Kathleen Richter¹, Halimuniyazi Haliduola¹, Jana Schockaert², Aurélie Mazy³, Nataliya Reznichenko⁴, Eric Guenzi⁵ and Fausto Berti⁶, ¹Alvotech, Jülich, Germany, ²ImmunXpert, Ghent, Belgium, ³ImmunXpert, Charleroi, Belgium, ⁴Military Hospital (Military Unit A3309) of Military-Medical Clinical Center of Southern Region, Zaporizhzhia, Ukraine, ⁵UGA Biopharma, Bonn, Germany, ⁶Alvotech, Zürich, Switzerland
Background/Purpose: A common reason for clinical development failure of biologic medicines is immunogenicity. Immunogenicity is traditionally measured by detecting neutralizing (NAb) anti-drug antibodies (ADA) in…
Abstract Number: 1614 • ACR Convergence 2022
Females with Non-Radiographic but Not with Radiographic Axial Spondyloarthritis Are Less Likely to Achieve Inactive Disease State Than Males: Results from a Multicountry Prospective Observational Study
Denis Poddubnyy¹, Joachim Sieper², Servet Akar³, Santiago Muñoz-Fernández⁴, Hildrun Haibel², Torsten Diekhoff⁵, Mikhail Protopopov⁶, Elisabeth Altmaier⁷, Fabiana Ganz⁸ and Robert Inman⁹, ¹Department of Gastroenterology, Infectious Diseases and Rheumatology, Charité – Universitätsmedizin Berlin, Berlin, Germany, ²Charité - Universitätsmedizin, Berlin, Berlin, Germany, ³Izmir Katip Celebi University School of Medicine, Izmir, Turkey, ⁴Servicio de Reumatología, Hospital Universitario Infanta Sofía, Universidad Europea, Madrid, Spain, ⁵Department of Radiology, Charité-Universitätsmedizin Berlin, Berlin, Germany, ⁶Charité Universitätsmedizin Berlin, Berlin, Germany, ⁷GKM Gesellschaft für Therapieforschung mbH, Munich, Germany, ⁸AbbVie, Inc., Luzern, Switzerland, ⁹University Health Network, Toronto, ON, Canada
Background/Purpose: Emerging evidence suggests that men and women experience axial spondyloarthritis (axSpA) differently. Some studies suggested that the probability of treatment response was lower in…
Abstract Number: 2273 • ACR Convergence 2022
Waning Vaccine Response After Primary Vaccine Series: Results from the Covid19 Vaccine Response in Rheumatology Patients (COVER) Study
Amy Mudano¹, Gary Cutter², Ted Mikuls³, Geoffrey Thiele⁴, Mark Law⁴, Bart Hamilton⁴, Michael Zikry⁵, Kelly Y. Chun⁶, Monique Bastidas⁷, Michael George⁸, Lisa Williams⁹, Kevin Winthrop¹⁰, Mark Busch¹¹, Stanley Cohen¹², Roman Czubatyj¹³, Rajesh Kataria¹⁴, Reshma Khan¹⁵, Soha Mousa¹⁶, Jose Pando¹⁷, Elizabeth Perkins¹⁸, Shanmugapriya Reddy¹⁹, Delfin Santos²⁰, Joy Schechtman²¹, Frank Scott²², Sucharitha Shanmugam²³, Atul Singhal²⁴, John Tesser²⁵, John Tower²⁶, Swamy Venuturupalli²⁷, Sean Joseph Wollaston²⁸, Conrad Ziembinski²⁹ and Jeffrey Curtis³⁰, ¹Illumination Health, Hoover, AL, ²University of Alabama at Birmingham, Birmingham, AL, ³Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE, ⁴University of Nebraska Medical Center, Omaha, NE, ⁵LabCorp, Burlington, NC, ⁶Labcorp, Calabasas, CA, ⁷LabCorp, Northridge, CA, ⁸University of Pennsylvania, Philadelphia, PA, ⁹Illumination Heath, Hoover, AL, ¹⁰Oregon Health & Science University, Portland, OR, ¹¹Family Arthritis Center-Jupiter, Jupiter, FL, ¹²Metroplex Clinical Research Center, Pittsburgh, PA, ¹³Arthritis Physicians LLC, Rochester Hills, MI, ¹⁴Southern Ohio, Wheelersburg, OH, ¹⁵Palm Beach Rheumatology and Wellness, Jupiter, FL, ¹⁶Arthritis and Rheumatology of Southwest Ohio, Liberty Township, OH, ¹⁷Rheumatology Consultants of DE, Lewes, DE, ¹⁸Rheumatology Care Center, Hoover, AL, ¹⁹Southwest Florida Rheumatology, Riverview, FL, ²⁰Rochester Rheumatology, Rochester Hills, MI, ²¹SunValley Arthritis Center, Peoria, AZ, ²²Arthritis Medical Center, Arroyo Grande, CA, ²³Rheumatology and Arthritis Care Center, Exton, PA, ²⁴Southwest Rheumatology Research, Mesquite, TX, ²⁵Arizona Arthritis & Rheumatology Associates, Phoenix, AZ, ²⁶Arthritis Physicians LLC, Rochester, MI, ²⁷Cedars-Sinai Medical Center, Los Angeles, CA, ²⁸Rheumatology Associates, North Hollywood, CA, ²⁹CZ Rheumatology, Coral Springs, FL, ³⁰Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Given possible increased risk of COVID-19 in patients with autoimmune conditions, there is a need to better understand the immunogenicity and safety of SARS-CoV-2…
Abstract Number: 0297 • ACR Convergence 2022
Effect of Upadacitinib, Adalimumab, and Placebo on Residual Pain Among Patients with Rheumatoid Arthritis Whose Inflammation Was Attenuated After Three and Six Months of Treatment
Louis Bessette¹, Adriana Kakehasi², Neil Basu³, David A. Walsh⁴, Andra Balanescu⁵, Clifton Bingham⁶, Andrew Garrison⁷, Ivan Lagunes⁸, sander strengholt⁹, Ralph Lippe¹⁰ and Maxime Dougados¹¹, ¹Centre de l'Ostoporose et de Rhumatologie de Québec, Québec, QC, Canada, ²Federal University of Minas Gerais, Hospital das Clínicas, Belo Horizonte, Brazil, ³University of Glasgow, Glasgow, Scotland, United Kingdom, ⁴University of Nottingham, Nottingham, United Kingdom, ⁵University of Medicine and Pharmacy Carol Davila, Bucharest, Romania, ⁶Johns Hopkins University, Baltimore, MD, ⁷AbbVie, Inc., North Chicago, IL, ⁸AbbVie, Inc., Mettawa, IL, ⁹AbbVie, Inc., Abcoude, Netherlands, ¹⁰AbbVie, Inc, Wiesbaden, Germany, ¹¹Université de Paris, Paris, France
Background/Purpose: Residual pain remains a challenge that prevents patients (pts) with RA from achieving a better quality of life. Current RA treatments have demonstrated efficacy…
Abstract Number: 0866 • ACR Convergence 2022
Outcomes of Children with Uveitis Associated with Autosomal Dominant Neovascular Inflammatory Vitreoretinopathy (ADNIV) Treated with Methotrexate and Infliximab
Sheila Angeles-Han¹, Grant Schulert¹, Megan Quinlan-Waters¹, Alexandra Duell¹, Jennifer Huggins¹, Tiffany Nguyen², Cameron Sapp², Sumit Sharma³, Sunil Srivastava⁴ and Arjun Sood², ¹Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Cincinnati Eye Institute, Cincinnati, OH, ³Cole Eye Institute, Cleveland Clinic, Cleveland, OH, ⁴Cole Eye Institute, Cleveland Clinic, Cincinnati, OH
Background/Purpose: Pediatric uveitis is commonly associated with rheumatic disease and can lead to sight-threatening complications. Initial treatment are glucocorticoids and subsequently methotrexate (MTX) and TNF…
Abstract Number: 1669 • ACR Convergence 2022
Comparing the Safety and Effectiveness of Methotrexate, TNF and IL6 Inhibitors for the Treatment of Checkpoint Inhibitor Arthritis
Anne Bass¹, Noha Abdel-Wahab², Pankti Reid³, Jeffrey Sparks⁴, Cassandra Calabrese⁵, Deanna Jannat-Khah, DrPH, MSPH⁶, Diviya Rajesh⁶, Nilasha Ghosh⁶, Komal Mushtaq⁷, Farah Al Haj⁸, Adewunmi Falohun⁹, Lydia Gedmintas¹⁰, Lindsey MacFarlane¹¹, Senada Arabelovic¹¹, Adi Diab², Ami Shah¹², Clifton O. Bingham III¹³, Karmela Kim Chan⁶ and Laura C. Cappelli¹⁴, ¹Hospital for Special Surgery/Weill Cornell Medicine, New York, NY, ²UT MD Anderson Cancer Center, Houston, TX, ³University of Chicago Medical Center, Chicago, IL, ⁴Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁵Cleveland Clinic Foundation, Cleveland Heights, OH, ⁶Hospital for Special Surgery, New York, NY, ⁷Cleveland Clinic, Cleveland, OH, ⁸Sinai Grace Hospital/ Detroit Medical Center, Detroit, MI, ⁹MD Anderson Cancer Center, Houston, TX, ¹⁰Brigham and Women's Hospital, Boston, MA, ¹¹Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ¹²Johns Hopkins Rheumatology, Baltimore, MD, ¹³Johns Hopkins University, Baltimore, MD, ¹⁴Johns Hopkins School of Medicine, Baltimore, MD
Background/Purpose: Immune checkpoint inhibitor associated arthritis (ICI-A) affects ∼4% of ICI-treated cancer patients and often persists. Given its long duration, it is important to identify…
Abstract Number: 0315 • ACR Convergence 2022
The Impact of Comorbidities on the Efficacy of IL-6 Inhibitor Olokizumab Compared to Adalimumab
Evgeny Nasonov¹, Eugen Feist², Michael Luggen³, Sergey Yakushin⁴, Daria Bukhanova⁵, Alina Egorova⁶, Sergey Grishin⁶, Mikhail Samsonov⁵ and Josef Smolen⁷, ¹V.A. Nasonova Research Institute of Rheumatology, Moscow, Russia, ²Helios Clinic Vogelsang-Gommern, cooperation partner of the Otto von Guericke University Magdeburg, Magdeburg, Germany, ³University Hospital/University of Cincinnati College of Medicine, Cincinnati, OH, ⁴Ryazan State Medical University named after academician I.P. Pavlov, Ryazan, Russia, ⁵R-Pharm JSC, Moscow, Russia, ⁶R-Pharm, Moscow, Russia, ⁷Medical University of Vienna, Vienna, Austria
Background/Purpose: Comorbid conditions may affect efficacy of treatment in patients with rheumatoid arthritis (RA). The aim of this analysis was to evaluate the impact of…
Abstract Number: 0887 • ACR Convergence 2022
Comparison of Drug Persistence and Incidence of Tuberculosis Between Tumor Necrosis Factor-α Inhibitors and Tocilizumab as the First-line Biological Treatment in Patients with Rheumatoid Arthritis Using the Korean Health Insurance Review and Assessment Service Database
Byung Wook Song, Dong-Hyuk Moon, Aran Kim and Seung-Geun Lee, Division of Rheumatology, Department of Internal Medicine, Pusan National University Hospital, Pusan National University School of Medicine, Busan, Republic of Korea
Background/Purpose: Drug persistence represents long-term therapeutic performance in real clinical setting and tuberculosis (TB) is one of the most important adverse events following biological treatments…
Abstract Number: 1728 • ACR Convergence 2022
Increased Frequency of Highly Differentiated T Effector Memory Cells Re-expressing CD45RA (Temra) and Cytomegalovirus Seropositivity Are Associated with Persistent Disease Specifically Refractory to Anti-TNF Therapy in Rheumatoid Arthritis
Su-Ann Yeoh, James Kimpton, Muhammad Shipa, Eleanor Hawkins, Arne Akbar and Michael Ehrenstein, University College London, London, United Kingdom
Background/Purpose: Enrichment of highly differentiated T cells have been reported in rheumatoid arthritis (RA) patients compared to healthy individuals. The role of highly differentiated T…
Abstract Number: 0372 • ACR Convergence 2022
Incidence and Risk of Overall Infections in Patients with Ankylosing Spondylitis Receiving Biologic Therapies: A Real-world Prospective Observational Study Using KOBIO Registry
Kyung Min Ko¹ and Su-Jin Moon², ¹International St. Mary's Hospital, Incheon, Republic of Korea, ²Catholic University of Korea, Seoul, Republic of Korea
Background/Purpose: Infection is a perpetual concern in patients treated with biological therapy. However, long-term real-world data on infectious profile of AS patients are lacking The…

« Previous Page
1
…
6
7
8
9
10
…
18
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].